Goldberg L I, Rajfer S I
Am Heart J. 1982 Apr;103(4 Pt 2):724-9. doi: 10.1016/0002-8703(82)90479-3.
Sympathomimetic amines are useful in the treatment of patients with ischemic heart disease complicated by heart failure and shock. These agents influence the cardiovascular system by action on alpha-adrenergic, beta-adrenergic, and dopamine receptors. Recent evidence has demonstrated the existence of subtypes of the classic adrenergic and dopamine receptors that mediate distinct physiologic effects. The relative actions of sympathomimetic amines on these receptors differ substantially, resulting in considerable variation in their cardiac and peripheral vascular effects. Two classes of sympathomimetic amines are being intensively investigated at present: (1) compounds acting predominantly on beta 1-adrenergic receptors (i.e., they increase cardiac contractile force with little or no peripheral vascular effects) and (2) compounds acting on both beta 1-adrenergic and dopamine receptors. Orally active compounds of these two classes have been synthesized recently and are now under study for the treatment of patients with heart failure. Results of preliminary studies with such components are briefly reviewed.
拟交感胺类药物在治疗合并心力衰竭和休克的缺血性心脏病患者中很有用。这些药物通过作用于α-肾上腺素能、β-肾上腺素能和多巴胺受体来影响心血管系统。最近的证据表明，经典肾上腺素能和多巴胺受体存在亚型，它们介导不同的生理效应。拟交感胺类药物对这些受体的相对作用差异很大，导致其心脏和外周血管效应有很大差异。目前正在深入研究两类拟交感胺类药物：（1）主要作用于β1-肾上腺素能受体的化合物（即它们增加心脏收缩力，对外周血管作用很小或没有作用）和（2）作用于β1-肾上腺素能受体和多巴胺受体的化合物。这两类口服活性化合物最近已合成，目前正在研究用于治疗心力衰竭患者。本文简要综述了使用此类成分的初步研究结果。
